Granulomatosis de Wegener: Clínica, diagnóstico y tratamiento a propósito de cinco casos

Ernesto Cairoli; Ricardo Silvariño; Enrique Méndez

Authors

Ernesto Cairoli Universidad de la República, Facultad de Medicina, Departamento Básico de Medicina, Profesor Adjunto. Clínica Médica, Profesor Adjunto
Ricardo Silvariño Universidad de la República, Facultad de Medicina, Clínica Médica, Asistente
Enrique Méndez Universidad de la República, Facultad de Medicina, Clínica Médica, Ex Profesor Agregado

Keywords:

WEGENER'S GRANULOMATOSIS

Abstract

Introduction: Wegener’s granulomatosis (WG) is a type of systemic granulomatous vasculitis primarily affecting the respiratory tract and kidneys.
Objectives: to study the signs and symptoms presented by patients cared for at Clinica Médica "C" of the Clinicas Hospital.
Methods: we conducted a descriptive, restrospective study including patients with a clinical and anatomopathological definitive diagnosis of WG. Five cases, diagnosed between 2002 and 2006, were analysed.
Results: average age of diagnosis was 51 years old (SD ± 24,5). Affection of the upper and lower respiratory tract was the most frequent clinical finding. Initial diagnosis in the 5 cases was respiratory tract infection. They all evidenced anticytoplasm of the neutrophil antibodies. (ACNA). Diagnosis was confirmed by a biopsy of the respiratory tract. Two patients developed malignant neoplasia prior to the diagnosis of WG. Average follow-up was 20 months after the diagnosis. Induction treatment of methylprednisolone and cyclophosphamide, and follow-up treatment with prednisone and azathioprine, were applied.
Conclusions: WG may be interpreted as a respiratory tract infection in its initial stage, when thorax tomography and positive ACNA findings constitute essential factors for diagnosis, and thus enable the orientation of biopsies toward "symptomatic sites" and the early initiation of immunosuppressor treatment.

References

(1) Jennette JC, Falk RJ. Small vessel vasculitis. N Engl J Med 1997; 337(21): 1512-23.
(2) Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368(9533): 404-18.
(3) Purriel P, Muras O, Acosta-Ferreira N, Vignale R. Granulomatosis de Wegener (a propósito de tres observaciones). Tórax 1964; 13: 175-95.
(4) Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2): 187-92.
(5) Ríos Blanco JJ, Gómez Cerezo J, Vázquez Muñoz E, Suárez García J, López Rodríguez M, Yébenes Gregorio L, et al. Estudio clínico-biológico y radiológico de la granulomatosis de Wegener en un hospital universitario. Rev Clin Esp 2005; 205(8): 367-73.
(6) Antunes T, Valente C. Wegener’s granulomatosis. J Bras Pneumol 2005; 31(Suppl. 1): S21-6.
(7) Cisternas M, Soto L, Jacobelli S, Marinovic MA, Vargas A, Sobarzo E, et al. Manifestaciones clínicas de la granulomatosis de Wegener y la poliangeítis microscópica en Santiago-Chile, 1990-2001. Rev Méd Chile 2005; 133(3): 273-8.
(8) Malamou-Mitsi V, Pappa LS, Paraskevaidis E, Pascho-poulos M, Drosos AA. Uterine cervical involvement in a patient with Wegener’s granulomatosis. Am J Med 2000; 109(1): 74-5.
(9) Cordier JF, Valeyre D, Guillevin L, Loire R, Brechot JM. Pulmonary Wegener’s granulomatosis: a clinical and imaging study of 77 cases. Chest 1990; 97(4): 906-12.
(10) Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006; 55(1): 146-9.
(11) Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology 2004; 43(12): 1532-5.
(12) Wung PK, Stone JH. Therapeutics of Wegener’s granulomatosis. Nat Clin Pract Rheumatol 2006; 2(4): 192-200.
(13) Langford CA. Wegener’s granulomatosis: current and upcoming therapies. Arthritis Res Ther 2003; 5(4): 180-91.